US20100009013A1 - Method of determining a chemotherapeutic regimen for non-small-cell lung cancer based on brca1 expression - Google Patents

Method of determining a chemotherapeutic regimen for non-small-cell lung cancer based on brca1 expression Download PDF

Info

Publication number
US20100009013A1
US20100009013A1 US12/496,257 US49625709A US2010009013A1 US 20100009013 A1 US20100009013 A1 US 20100009013A1 US 49625709 A US49625709 A US 49625709A US 2010009013 A1 US2010009013 A1 US 2010009013A1
Authority
US
United States
Prior art keywords
brca1
patient
lung cancer
cell lung
small
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/496,257
Inventor
Rafael Rosell Costa
Miquel TARON ROCA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pangaea Biotech SL
Original Assignee
Pangaea Biotech SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pangaea Biotech SL filed Critical Pangaea Biotech SL
Priority to US12/496,257 priority Critical patent/US20100009013A1/en
Publication of US20100009013A1 publication Critical patent/US20100009013A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification

Definitions

  • the present invention relates to the use of BRCA1 levels of expression as a prognostic marker of chemotherapy response in non small cell lung carcinoma (NSCLC) patients, to methods of selecting chemotherapy and of classifying patients accordingly, and to the use of chemotherapeutic agents for the treatment of NSCLC patients.
  • NSCLC non small cell lung carcinoma
  • Non-small-cell lung cancer accounts for approximately 80% of all lung cancers, with 1.2 million new cases worldwide each year. NSCLC resulted in more than one million deaths worldwide in 2001 and is the leading cause of cancer-related mortality in both men and women (31% and 25%, respectively). The prognosis of advanced NSCLC is dismal. A recent Eastern Cooperative Oncology Group trial of 1155 patients showed no differences among the chemotherapies used: cisplatin/paclitaxel, cisplatin/gemcitabine, cisplatin/docetaxel and carboplatin/paclitaxel. Overall median time to progression was 3.6 months, ands median survival was 7.9 months.
  • Five-year survival is around 25% for pathologic stage IIB (T1-2N1M0, T3N0M0), 13% for stage IIIA (T3N1M0, T1-2-3N2M0), and a low 7% for stage IIIB (T4N0-1-2M0).
  • DDP cisplatin
  • carboplatin are among the most widely used cytotoxic anticancer drugs.
  • resistance to these drugs through de novo or induced mechanisms undermines their curative potential.
  • These drugs disrupt DNA structure through formation of intrastrand adducts.
  • Resistance to platinum agents such as DDP has been attributed to enhanced tolerance to platinum adducts, decreased drug accumulation, or enhanced DNA repair.
  • neoadjuvant chemotherapy induces tumor shrinkage and sterilizes metastatic lymph nodes, leading to pathologic downstaging in approximately 33% and complete pathologic remission in up to 14% of patients.
  • NSCLC Non-Small Cell Lung Carcinoma
  • BRCA1 Breast Cancer 1 plays a crucial role in DNA repair, and decreased BRCA1 mRNA expression has been observed in both sporadic and hereditary breast cancers (Kennedy R D, et al. (2002) Lancet, 360, 1007-1014: “ BRCA 1 : mechanisms of inactivation and implications for management of patients ”). However, its potential effect in lung cancer has never been examined.
  • BRCA1 is implicated in transcription-coupled nucleotide excision repair (TC-NER), and modulation of its expression leads to modification of TC-NER and hence to radio- and chemoresistance.
  • Upregulation of BRCA1 expression led to increased cisplatin resistance in the SKOV-3 human ovarian cancer cell line (Husain A, et al. (1998) Cancer Res., 58, 1120-1123: “ BRCA 1 up - regulation is associated with repair - mediated resistance to cis - diamminedichloroplatinum ( II )”), and restoration of BRCA1 in the BRCA1-negative HCC1937 human breast cancer cell line restored radioresistance.
  • TC-NER transcription-coupled nucleotide excision repair
  • BRCA1 is also involved in homologous recombination repair (HRR) and non-homologous end joining in response to DNA damage.
  • HRR homologous recombination repair
  • BRCA1-associated genome surveillance complex which contains a number of mismatch repair proteins, indicating a potential role for BRCA1 in mismatch repair.
  • BRCA1 may also be a regulator of mitotic spindle assembly, as BRCA1 and ⁇ -tubulin colocalize to the microtubules of the mitotic spindle and to the centrosomes.
  • BRCA1 expression has been linked to apoptosis through the c-Jun N-terminal kinase pathway, which is activated by cisplatin-induced DNA damage; inhibition of this pathway increased cisplatin sensitivity in cell lines.
  • RT-QPCR real-time quantitative polymerase chain reaction
  • BRCA1 mRNA expression level is a good marker of differential sensitivity, providing an important tool for customizing NSCLC chemotherapy in order to improve survival in this very common and fatal disease.
  • the present invention provides a screening method for selecting an effective chemotherapy for the treatment of a patient suffering from non-small-cell lung cancer (NSCLC), comprising the steps:
  • a chemotherapeutic treatment selected from the group formed by cisplatin, carboplatin, gemcitabine, paclitaxel, docetaxel and combinations thereof, based on results of the comparison of the BRCA1 gene expression level with the predetermined threshold level.
  • the invention provides a method for classifying patients suffering from non-small-cell lung cancer comprising:
  • the patient is suffering NSCLC prior to surgery.
  • the predetermined threshold level is obtained by dividing in 4 quartiles the levels of expression of BRCA1 measured in a collection of tumor tissue in biopsy samples from NSCLC patients, previous to the neoadjuvant chemotherapeutic treatment and defining a level of “low” for the bottom quartile, “normal” for the middle quartiles or “high” for the top quartile of BRCA1 levels of expression.
  • the collection has at least 40 samples, more preferably at least 50 samples. It is preferred that the tissue sample is a fixed and paraffin-embedded sample.
  • the invention is also directed to the use of cisplatin as a single agent or as a gemcitabine/cisplatin combination in the manufacture of a medicament for the treatment of a NSCLC patient having low expression levels of the BRCA1 gene.
  • the invention provides the use of docetaxel or paclitaxel as single agent or a combination of gemcitabine/paclitaxel or gemcitabine/docetaxel in the manufacture of a medicament for the treatment of a NSCLC patient having high expression levels of the BRCA1 gene.
  • FIG. 1 Example of the amplification plots ( ⁇ Rn versus cycle number) of ⁇ -actin (A) and BRCA1 (B) cDNA. Both figures correspond to serial dilutions of cDNA obtained from one of the samples. C and D show examples of the validation curves for relative quantification. Different primers and probe concentrations were assayed for ⁇ -actin and BRCA1 gene expression analysis to obtain the optimal PCR efficiency. In order for the relative quantification to be valid, the amplification efficiency of the target (BRCA1) and the reference ( ⁇ -actin) amplification must be approximately equal.
  • a sensitive method for assessing whether two amplicons have the same amplification efficiency is to see how ⁇ Ct varies when using a serial dilution of a control cDNA.
  • Several runs with serial dilutions were performed to confirm that the slope ⁇ 0.1 in the plot ⁇ C t value versus Log 10 input amount cDNA, defined as Ct BRCA1 in each dilution minus Ct ⁇ -actin in the same dilution (C).
  • FIG. 2 Median survival according to quartiles of BRCA1 mRNA expression levels. Median survival was not reached for those in the bottom quartile, while it was 37.8 months for those in the middle quartiles, and 12.7 months for those in the top quartile.
  • BRCA1 mRNA expression could also play an important role in predicting differential chemotherapy sensitivity in lung cancer, in particular NSCLC.
  • cytotoxic chemotherapeutic agents especially antimetabolites such as gemcitabine and agents that damage DNA in the manner of platinating agents has been assayed by examining the mRNA expressed from genes involved in nucleotide synthesis and DNA repair in humans.
  • the present invention resides in part in the finding that the amount of BRCA1 mRNA is correlated with resistance to cisplatin agents. Tumors expressing high levels of BRCA1 mRNA are considered likely to be resistant to platinum-based chemotherapy. On the other hand, those tumors expressing low amounts of BRCA1 mRNA are likely to be sensitive to platinum-based chemotherapy. A patient's tumor BRCA1 mRNA expression level is judged by comparing it to a predetermined threshold expression level.
  • the present method can be applied to any type of tissue from a patient.
  • tissue from a patient For examination of resistance of tumor tissue, it is preferable to examine the tumor tissue.
  • a portion of normal tissue from the patient from which the tumor is obtained is also examined. Preferably this is done prior to the chemotherapy.
  • tumor cells are preferably isolated from the patient. Tumors or portions thereof are surgically resected from the patient or obtained by routine biopsy. RNA isolated from frozen or fresh samples is extracted from the cells by any of the methods typical in the art, for example, Sambrook, Fischer and Maniatis, Molecular Cloning, a laboratory manual, (2nd ed.), Cold Spring Harbor Laboratory Press, New York, (1989). Preferably, care is taken to avoid degradation of the RNA during the extraction process.
  • the expression level is determined using RNA obtained from a formalin-fixed, paraffin-embedded tissue sample.
  • tissue samples are envisaged, such as fresh tissue from a biopsy or blood samples depending on their availability.
  • RNA may be isolated from an archival pathological sample or biopsy sample which is first deparaffinized.
  • An exemplary deparaffinization method involves washing the paraffinized sample with an organic solvent, such as xylene, for example.
  • Deparaffinized samples can be rehydrated with an aqueous solution of a lower alcohol. Suitable lower alcohols, for example include, methanol, ethanol, propanols, and butanols.
  • Deparaffinized samples may be rehydrated with successive washes with lower alcoholic solutions of decreasing concentration, for example. Alternatively, the sample is simultaneously deparaffinized and rehydrated. The sample is then lysed and RNA is extracted from the sample.
  • RT-PCR reverse transcription polymerase chain reaction
  • the values for “low,” “normal,” or “high” levels of expression are determined by comparison to reproducible standards which correspond to the median value of expression levels of BRCA1 measured in a collection of tumor tissue in biopsy samples from cancer patients, previous to the neoadjuvant chemotherapeutic treatment. Once this median value is established, the level of this marker expressed in tumor tissues from patients can be compared with this median value, and thus be assigned a level of “low,” “normal” or “high.”
  • the measure of relative gene expression is preferably made by using ⁇ -actin as an endogenous control, although other methods known in the art can be used, as long as relative levels of BRCA1 can be assigned to the samples.
  • Levels of mRNA or the corresponding protein can be measured to obtain the relative level of BRCA1 expression. Standard methods of measurement well known in the art are used, see for example EP 1 381 681 incorporated by reference herein in its entirety.
  • relative gene expression quantification is calculated according to the comparative Ct method using ⁇ -actin as an endogenous control and commercial RNA controls as calibrators. Final results, are determined according to the formula 2 ⁇ ( ⁇ Ct sample ⁇ Ct calibrator) , where ACT values of the calibrator and sample are determined by subtracting the C T value of the target gene from the value of the ⁇ -actin gene.
  • the collection of samples from which the reference level is derived will preferably be constituted from patient suffering from NSCLC.
  • the one described in the examples which is statistically representative was constituted with 55 samples from NSCLC patients. In other cases it can contain a different number of samples.
  • the chemotherapy agents to be used in the methods of this invention will be administered in doses commonly employed clinically. Such doses will be calculated in the normal fashion, for example on body surface area.
  • Gemcitabine is the generic name assigned to 2′-deoxy-2′,2′-difluoro-cytidine. It is commercially available as the monohydrochloride salt, and as the beta-isomer. It is also known chemically as 1-(4-amino-2-oxo-1H-pyrimidin-1-yl)-2-desoxy-2,2-difluororibose. Gemcitabine is disclosed in U.S. Pat. Nos. 4,808,614 and 5,464,826, which are incorporated herein by reference. Gemcitabine will likewise be administered at doses comparable to those routinely utilized clinically. For example, the initial dose of gemcitabine, typically as the hydrochloride salt, will be about 1000-1250 mg/m 2 of body surface area.
  • This product is routinely formulated as a sterile solution and is administered by intravenous infusion, generally over about a 30-minute period, with about 2 to 4 weekly doses, with courses repeated about every 28 to 30 days.
  • the dose of 1000-1250 mg/m 2 can be given for up to about 7 weeks, according to this treatment regimen, or until undesirable side effects are observed.
  • Other salt forms can be utilized if desired, for example, the hydrobromide, monophosphate, sulfate, malonate, citrate, and succinate are readily prepared.
  • Cisplatin is the generic name for cis-diaminodichloroplatinum and is described in U.S. Pat. No. 5,562,925, which is incorporated herein by reference. Cisplatin generally is formulated as a sterile solution for injection, and is routinely administered at a dose of about 50 to 100 mg/m 2 , given intravenously. This cycle can be repeated for about every 4 to 8 weeks.
  • the appropriate chemotherapeutic agents for a patient suffering of NSCLC can be selected according to his levels of BRCA1 expression.
  • Patients with low BRCA1 mRNA levels can benefit from single-agent cisplatin, while those with high levels would benefit from single-agent docetaxel or paclitaxel.
  • high BRCA1 levels may diminish the synergism between taxanes and cisplatin or carboplatin.
  • sensitivity to antimetabolites, such as gemcitabine may not be affected by BRCA1 levels, gemcitabine/cisplatin synergism may be partially abrogated in tumors with high BRCA1 mRNA levels, but these tumors may benefit from the synergism observed between taxanes and gemcitabine.
  • neoadjuvant chemotherapy was indicated after evaluation by a thoracic surgeon, a radiologist, a medical oncologist, and a radiation oncologist.
  • a thoracotomy was performed within four to five weeks after the last chemotherapy cycle; the surgical procedure was based on the extent of tumor at the time of the initial presentation.
  • Template cDNA was added to Taqman Universal Master Mix (AB; Applied Biosystems, Foster City, Calif., USA) in a 12.5- ⁇ l reaction with specific primers and probe for each gene.
  • the primer and probe sets were designed using Primer Express 2.0 Software (AB). Quantification of gene expression was performed using the ABI Prism 7900HT Sequence Detection System (AB). Primers and probe for BRCA1 mRNA expression analysis were designed according to the Ref Seq NM — 007294 (www.ncbi.nlm.nih.gov/LocusLink).
  • Forward primer is located in exon 8 (position 4292 bp to 4317 bp), reverse primer in exon 9 (position 4336 bp to 4360 bp), and probe in the exon 8/9 junction (position 4313 bp to 4333 bp).
  • the PCR product size generated with these primers was 69 bp.
  • the primers and 5'labeled fluorescent reporter dye (6FAM) probe were as follows: ⁇ -actin: forward 5′ TGA GCG CGG CTA CAG CTT 3′, reverse 5′ TCC TTA ATG TCA CGC ACG ATT T 3′, probe 5′ ACC ACC ACG GCC GAG CGG 3′; BRCA1: forward 5′GGC TAT CCT CTC AGA GTG ACA TTT TA 3′, reverse 5′ GCT TTA TCA GGT TAT GTT GCA TGG T 3′, probe 5′CCA CTC AGC AGA GGG 3′.
  • Relative gene expression quantification was calculated according to the comparative Ct method using ⁇ -actin as an endogenous control and commercial RNA controls (Stratagene, La Jolla, Calif.) as calibrators. Final results, were determined as follows: 2 ⁇ ( ⁇ Ct sample ⁇ Ct calibrator) , where ⁇ C T values of the calibrator and sample are determined by subtracting the C T value of the target gene from the value of the ⁇ -actin gene. In all experiments, only triplicates with a standard deviation (SD) of the Ct value ⁇ 0.20 were accepted. In addition, for each sample analyzed, a retrotranscriptase minus control was run in the same plate to assure lack of genomic DNA contamination ( FIG. 1 ).
  • Amplification plots obtained for the genes BRCA1 and ⁇ -actin are shown in FIG. 1 .
  • Values ranged from 0.28 to 0.61 (interpatient coefficient of variation, 30.7%) for the 15 patients in the bottom quartile, from 0.65 to 1.20 (interpatient coefficient of variation, 17.4%) for the 14 patients in the second quartile, from 1.23 to 2.37 (interpatient coefficient of variation, 17.7%) for the 14 patients in the third quartile, and from 2.45 to 10.43 (interpatient coefficient of variation, 54.7%) for the 12 patients in the top quartile. Due to the similar values and interpatient coefficients of variation observed in the second and third quartiles, these two groups were merged for statistical analyses.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention relates to a screening method for classifying patients and for selecting an effective chemotherapy for the treatment of a patient suffering from non-small-cell lung cancer (NSCLC), based on the use of his levels of BRCA1 expression to predict the outcome of chemotherapy.

Description

  • This application is a continuation of U.S. patent application Ser. No. 10/977,951, filed on Oct. 29, 2004, the entire disclosure of which is herein incorporated by reference in its entirety.
    • FIELD OF THE INVENTION
  • The present invention relates to the use of BRCA1 levels of expression as a prognostic marker of chemotherapy response in non small cell lung carcinoma (NSCLC) patients, to methods of selecting chemotherapy and of classifying patients accordingly, and to the use of chemotherapeutic agents for the treatment of NSCLC patients.
    • BACKGROUND OF THE INVENTION
  • Non-small-cell lung cancer (NSCLC) accounts for approximately 80% of all lung cancers, with 1.2 million new cases worldwide each year. NSCLC resulted in more than one million deaths worldwide in 2001 and is the leading cause of cancer-related mortality in both men and women (31% and 25%, respectively). The prognosis of advanced NSCLC is dismal. A recent Eastern Cooperative Oncology Group trial of 1155 patients showed no differences among the chemotherapies used: cisplatin/paclitaxel, cisplatin/gemcitabine, cisplatin/docetaxel and carboplatin/paclitaxel. Overall median time to progression was 3.6 months, ands median survival was 7.9 months.
  • The overall five-year survival of patients with NSCLC has remained at less than 15% for the past 20 years. Stage grouping of TNM subsets (T=primary tumor; N=regional lymph nodes; M=distant metastases) permits the identification of patient groups with similar prognosis and treatment options. Five-year survival is around 25% for pathologic stage IIB (T1-2N1M0, T3N0M0), 13% for stage IIIA (T3N1M0, T1-2-3N2M0), and a low 7% for stage IIIB (T4N0-1-2M0).
  • Currently, cisplatin (DDP) and carboplatin are among the most widely used cytotoxic anticancer drugs. However, resistance to these drugs through de novo or induced mechanisms undermines their curative potential. These drugs disrupt DNA structure through formation of intrastrand adducts. Resistance to platinum agents such as DDP has been attributed to enhanced tolerance to platinum adducts, decreased drug accumulation, or enhanced DNA repair.
  • Small randomized studies of cisplatin-based chemotherapy followed by surgery in clinical stage IIIA (Pass H I, et al. (1992) Ann. Thor. Surg., 53, 992-998: “Randomized trial of neoadjuvant therapy for lung cancer: interim analysis”) or stage IIB-IIIB (Rosell R, et al. (1994)N. Engl. J. Med., 330, 153-158 “A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer”) showed remarkable improvement in survival over NSCLC patients treated either with surgery alone or with surgery followed by radiotherapy. Event-free survival was similar in the two studies (12.7 and 20 months in the neoadjuvant chemotherapy arm and 5.8 and 5 months in the surgery arm). In general, neoadjuvant chemotherapy induces tumor shrinkage and sterilizes metastatic lymph nodes, leading to pathologic downstaging in approximately 33% and complete pathologic remission in up to 14% of patients.
  • During the past 30 years medical oncologists have focused to optimise the outcome of cancer patients and it is just now that the new technologies available are allowing to investigate polymorphisms, gene expression levels and gene mutations aimed to predict the impact of a given therapy in different groups of cancer patients to tailor chemotherapy. Representative examples include the relation between the TS mRNA expression and the response and the survival with antifolates (see EP 1 381 691), beta tubulin III mRNA levels and response to tubulin interacting agents, PTEN methylation and resistance to CPT-11 and STAT3 over expression and resistance to EGF interacting agents.
  • Although a wealth of data indicates that changes in the level of several gene transcripts can modulate differential chemosensitivity between NSCLC patients with the same TNM subset, at present no predictive genetic markers of chemotherapy response are used for tailoring treatment. To further improve the survival rate in patients with Non-Small Cell Lung Carcinoma (NSCLC), their prognostic classification based on molecular alterations is crucial. Such classification will provide more accurate and useful diagnostic tools and, eventually, more effective therapeutic options.
  • Breast Cancer 1 (BRCA1) plays a crucial role in DNA repair, and decreased BRCA1 mRNA expression has been observed in both sporadic and hereditary breast cancers (Kennedy R D, et al. (2002) Lancet, 360, 1007-1014: “BRCA1: mechanisms of inactivation and implications for management of patients”). However, its potential effect in lung cancer has never been examined.
  • BRCA1 is implicated in transcription-coupled nucleotide excision repair (TC-NER), and modulation of its expression leads to modification of TC-NER and hence to radio- and chemoresistance. Upregulation of BRCA1 expression led to increased cisplatin resistance in the SKOV-3 human ovarian cancer cell line (Husain A, et al. (1998) Cancer Res., 58, 1120-1123: “BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II)”), and restoration of BRCA1 in the BRCA1-negative HCC1937 human breast cancer cell line restored radioresistance. BRCA1 is also involved in homologous recombination repair (HRR) and non-homologous end joining in response to DNA damage. In addition, it is a component of a large DNA repair complex termed the BRCA1-associated genome surveillance complex, which contains a number of mismatch repair proteins, indicating a potential role for BRCA1 in mismatch repair. BRCA1 may also be a regulator of mitotic spindle assembly, as BRCA1 and β-tubulin colocalize to the microtubules of the mitotic spindle and to the centrosomes. Finally, enhanced BRCA1 expression has been linked to apoptosis through the c-Jun N-terminal kinase pathway, which is activated by cisplatin-induced DNA damage; inhibition of this pathway increased cisplatin sensitivity in cell lines. Decreased BRCA1 mRNA expression in a breast cancer cell line, as determined by real-time quantitative polymerase chain reaction (RT-QPCR), led to greater sensitivity to cisplatin and etoposide but to greater resistance to the microtubule-interfering agents paclitaxel and vincristine (Lafarge S, et al. (2001) Oncogene, 20, 6597-6606: “Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway”). Recently, reconstitution of wild-type BRCA1 into the BRCA1-negative HCC1937 breast cancer cell line resulted in a 20-fold increase in cisplatin resistance and, in contrast, in a 1000-10,000-fold increase in sensitivity to antimicrotubule drugs (paclitaxel and vinorelbine).
  • Mouse models carrying conditional disruption of BRCA1 were highly sensitive to doxorubicin and gamma irradiation but resistant to tamoxifen, providing additional evidence for differential chemosensitivity linked to BRCA1 expression. When BRCA1 expression was examined by semi-quantitative PCR in women with sporadic breast cancer, lower BRCA1 mRNA levels (bottom quartile) were associated with a higher frequency of distant metastases (Seery L T, et al. (1999) Int. J. Cancer (Pred. Oncol.), 84, 258-262: “BRCA1 expression levels predict distant metastasis of sporadic breast cancers”.
  • Despite the wealth of data in cell lines and mouse models, only one small study has examined the correlation of BRCA1 and BRCA2 mRNA expression with response to chemotherapy in the clinical setting (Egawa C., (2001) Int. J. Cancer (Pred. Oncol.), 95, 255-259: “Decreased expression of BRCA2 mRNA predicts favorable response to docetaxel in breast cancer”). Among 25 women with docetaxel-treated locally advanced or metastatic breast cancer, only BRCA2 mRNA levels were significantly lower in responders than in non-responders, though a slight difference was also observed for BRCA1.
    • SUMMARY OF THE INVENTION
  • It is an object of the invention to provide a tool for use in predicting differential chemosensitivity and tailoring chemotherapy in NSCLC. We have found that BRCA1 mRNA expression level is a good marker of differential sensitivity, providing an important tool for customizing NSCLC chemotherapy in order to improve survival in this very common and fatal disease.
  • In one aspect the present invention provides a screening method for selecting an effective chemotherapy for the treatment of a patient suffering from non-small-cell lung cancer (NSCLC), comprising the steps:
  • a) isolating mRNA from a tissue sample of the patient;
  • b) determining a gene expression level of BRCA1 in the sample;
  • c) comparing the BRCA1 gene expression levels in the sample with a predetermined threshold level for the BRCA1 gene expression;
  • d) and selecting a chemotherapeutic treatment selected from the group formed by cisplatin, carboplatin, gemcitabine, paclitaxel, docetaxel and combinations thereof, based on results of the comparison of the BRCA1 gene expression level with the predetermined threshold level.
  • In a second aspect the invention provides a method for classifying patients suffering from non-small-cell lung cancer comprising:
  • a) isolating mRNA from a tissue sample of the patient;
  • b) determining a gene expression level of BRCA1 in the sample;
  • c) comparing the BRCA1 gene expression levels in the sample with predetermined threshold levels for the BRCA1 gene expression;
  • d) and classifying the patients in 3 groups defined as “low”, “normal” or high” according to the results of the comparison of the BRCA1 gene expression level with the predetermined threshold level.
  • In one embodiment the patient is suffering NSCLC prior to surgery.
  • In another embodiment the predetermined threshold level is obtained by dividing in 4 quartiles the levels of expression of BRCA1 measured in a collection of tumor tissue in biopsy samples from NSCLC patients, previous to the neoadjuvant chemotherapeutic treatment and defining a level of “low” for the bottom quartile, “normal” for the middle quartiles or “high” for the top quartile of BRCA1 levels of expression.
  • To give good results the collection has at least 40 samples, more preferably at least 50 samples. It is preferred that the tissue sample is a fixed and paraffin-embedded sample.
  • The invention is also directed to the use of cisplatin as a single agent or as a gemcitabine/cisplatin combination in the manufacture of a medicament for the treatment of a NSCLC patient having low expression levels of the BRCA1 gene.
  • In another aspect the invention provides the use of docetaxel or paclitaxel as single agent or a combination of gemcitabine/paclitaxel or gemcitabine/docetaxel in the manufacture of a medicament for the treatment of a NSCLC patient having high expression levels of the BRCA1 gene.
    • BRIEF DESCRIPTION OF THE FIGURES
  • FIG. 1. Example of the amplification plots (ΔRn versus cycle number) of β-actin (A) and BRCA1 (B) cDNA. Both figures correspond to serial dilutions of cDNA obtained from one of the samples. C and D show examples of the validation curves for relative quantification. Different primers and probe concentrations were assayed for β-actin and BRCA1 gene expression analysis to obtain the optimal PCR efficiency. In order for the relative quantification to be valid, the amplification efficiency of the target (BRCA1) and the reference (β-actin) amplification must be approximately equal. A sensitive method for assessing whether two amplicons have the same amplification efficiency is to see how ΔCt varies when using a serial dilution of a control cDNA. We performed two validations: one using control cDNA, another using cDNA from paraffin-embedded samples. Several runs with serial dilutions were performed to confirm that the slope <0.1 in the plot ΔCt value versus Log10 input amount cDNA, defined as Ct BRCA1 in each dilution minus Ct β-actin in the same dilution (C). For primers and probe sets, the slope of the plot Ct versus Log10 input amount cDNA needed to be between −3.25 and −3.45, since a slope of −3.33 represents 100% efficiency. The slopes in our assays were −3.36 for β-actin and −3.32 for BRCA1, with a correlation coefficient (R2)>0.98 (D).
  • FIG. 2. Median survival according to quartiles of BRCA1 mRNA expression levels. Median survival was not reached for those in the bottom quartile, while it was 37.8 months for those in the middle quartiles, and 12.7 months for those in the top quartile.
    •  DETAILED DESCRIPTION OF THE INVENTION
  • Based on the evidence for the role of BRCA1 in breast and ovarian cancer, we investigated if BRCA1 mRNA expression could also play an important role in predicting differential chemotherapy sensitivity in lung cancer, in particular NSCLC. The resistance of tumor cells to cytotoxic chemotherapeutic agents, especially antimetabolites such as gemcitabine and agents that damage DNA in the manner of platinating agents has been assayed by examining the mRNA expressed from genes involved in nucleotide synthesis and DNA repair in humans.
  • The present invention resides in part in the finding that the amount of BRCA1 mRNA is correlated with resistance to cisplatin agents. Tumors expressing high levels of BRCA1 mRNA are considered likely to be resistant to platinum-based chemotherapy. On the other hand, those tumors expressing low amounts of BRCA1 mRNA are likely to be sensitive to platinum-based chemotherapy. A patient's tumor BRCA1 mRNA expression level is judged by comparing it to a predetermined threshold expression level.
  • We examined the potential predictive value of BRCA1 mRNA expression in resected specimens from stage IIB, IIIA and IIIB NSCLC patients treated with neoadjuvant gemcitabine/cisplatin followed by surgery. Surprisingly, we found that there is a correlation and that BRCA1 is a predictive marker of differential chemosensitivity and BRCA1 mRNA assessment provides an important method for customizing NSCLC chemotherapy.
  • The present method can be applied to any type of tissue from a patient. For examination of resistance of tumor tissue, it is preferable to examine the tumor tissue. In a preferred embodiment, a portion of normal tissue from the patient from which the tumor is obtained, is also examined. Preferably this is done prior to the chemotherapy.
  • In performing the methods of the present invention, tumor cells are preferably isolated from the patient. Tumors or portions thereof are surgically resected from the patient or obtained by routine biopsy. RNA isolated from frozen or fresh samples is extracted from the cells by any of the methods typical in the art, for example, Sambrook, Fischer and Maniatis, Molecular Cloning, a laboratory manual, (2nd ed.), Cold Spring Harbor Laboratory Press, New York, (1989). Preferably, care is taken to avoid degradation of the RNA during the extraction process.
  • In a particular embodiment, the expression level is determined using RNA obtained from a formalin-fixed, paraffin-embedded tissue sample. Other tissue samples are envisaged, such as fresh tissue from a biopsy or blood samples depending on their availability.
  • Fixed and paraffin-embedded tissue samples are preferred because they are broadly available from tissue sample archives in the field of Oncology. RNA may be isolated from an archival pathological sample or biopsy sample which is first deparaffinized. An exemplary deparaffinization method involves washing the paraffinized sample with an organic solvent, such as xylene, for example. Deparaffinized samples can be rehydrated with an aqueous solution of a lower alcohol. Suitable lower alcohols, for example include, methanol, ethanol, propanols, and butanols. Deparaffinized samples may be rehydrated with successive washes with lower alcoholic solutions of decreasing concentration, for example. Alternatively, the sample is simultaneously deparaffinized and rehydrated. The sample is then lysed and RNA is extracted from the sample.
  • While all techniques of gene expression profiling, as well as proteomics techniques, are suitable for use in performing the foregoing aspects of the invention, the gene expression levels are often determined by reverse transcription polymerase chain reaction (RT-PCR).
  • The values for “low,” “normal,” or “high” levels of expression are determined by comparison to reproducible standards which correspond to the median value of expression levels of BRCA1 measured in a collection of tumor tissue in biopsy samples from cancer patients, previous to the neoadjuvant chemotherapeutic treatment. Once this median value is established, the level of this marker expressed in tumor tissues from patients can be compared with this median value, and thus be assigned a level of “low,” “normal” or “high.”
  • The measure of relative gene expression is preferably made by using β-actin as an endogenous control, although other methods known in the art can be used, as long as relative levels of BRCA1 can be assigned to the samples. Levels of mRNA or the corresponding protein can be measured to obtain the relative level of BRCA1 expression. Standard methods of measurement well known in the art are used, see for example EP 1 381 681 incorporated by reference herein in its entirety.
  • In one embodiment relative gene expression quantification is calculated according to the comparative Ct method using β-actin as an endogenous control and commercial RNA controls as calibrators. Final results, are determined according to the formula 2−(ΔCt sample−ΔCt calibrator), where ACT values of the calibrator and sample are determined by subtracting the CT value of the target gene from the value of the β-actin gene.
  • The collection of samples from which the reference level is derived will preferably be constituted from patient suffering from NSCLC. For example, the one described in the examples which is statistically representative was constituted with 55 samples from NSCLC patients. In other cases it can contain a different number of samples.
  • In one example, we used real-time quantitative PCR to determine BRCA1 mRNA levels in 55 surgically resected tumors of non-small-cell lung cancer patients who had received neoadjuvant gemcitabine/cisplatin chemotherapy, and divided the gene expression values into quartiles. These quartiles represent the different threshold levels. When results were correlated with outcome, median survival was not reached for the 15 patients in the bottom quartile, while for the 28 in the two middle quartiles, it was 37.8 months (95% CI, 10.6-65), and for the 12 patients in the top quartile, it was 12.7 months (95% CI, 0.28-28.8) (P=0.01). Moreover, patients with BRCA1 levels in the bottom quartile and those with levels in the two middle quartiles both had a significantly decreased risk of death compared to those in the top quartile (hazard ratio=0.187 [P=0.008] and 0.382 [P=0.042], respectively).
  • The chemotherapy agents to be used in the methods of this invention will be administered in doses commonly employed clinically. Such doses will be calculated in the normal fashion, for example on body surface area.
  • Gemcitabine is the generic name assigned to 2′-deoxy-2′,2′-difluoro-cytidine. It is commercially available as the monohydrochloride salt, and as the beta-isomer. It is also known chemically as 1-(4-amino-2-oxo-1H-pyrimidin-1-yl)-2-desoxy-2,2-difluororibose. Gemcitabine is disclosed in U.S. Pat. Nos. 4,808,614 and 5,464,826, which are incorporated herein by reference. Gemcitabine will likewise be administered at doses comparable to those routinely utilized clinically. For example, the initial dose of gemcitabine, typically as the hydrochloride salt, will be about 1000-1250 mg/m2 of body surface area. This product is routinely formulated as a sterile solution and is administered by intravenous infusion, generally over about a 30-minute period, with about 2 to 4 weekly doses, with courses repeated about every 28 to 30 days. The dose of 1000-1250 mg/m2 can be given for up to about 7 weeks, according to this treatment regimen, or until undesirable side effects are observed. Other salt forms can be utilized if desired, for example, the hydrobromide, monophosphate, sulfate, malonate, citrate, and succinate are readily prepared.
  • Cisplatin is the generic name for cis-diaminodichloroplatinum and is described in U.S. Pat. No. 5,562,925, which is incorporated herein by reference. Cisplatin generally is formulated as a sterile solution for injection, and is routinely administered at a dose of about 50 to 100 mg/m2, given intravenously. This cycle can be repeated for about every 4 to 8 weeks.
  • Thus according to the invention the appropriate chemotherapeutic agents for a patient suffering of NSCLC can be selected according to his levels of BRCA1 expression. Patients with low BRCA1 mRNA levels can benefit from single-agent cisplatin, while those with high levels would benefit from single-agent docetaxel or paclitaxel. In contrast, high BRCA1 levels may diminish the synergism between taxanes and cisplatin or carboplatin. While sensitivity to antimetabolites, such as gemcitabine, may not be affected by BRCA1 levels, gemcitabine/cisplatin synergism may be partially abrogated in tumors with high BRCA1 mRNA levels, but these tumors may benefit from the synergism observed between taxanes and gemcitabine.
  • The invention being thus described, practice of the invention is illustrated by the experimental examples provided below. The skilled practitioner will realize that the materials and methods used in the illustrative examples can be modified in various ways.
    • EXAMPLES Patients
  • In all patients, neoadjuvant chemotherapy was indicated after evaluation by a thoracic surgeon, a radiologist, a medical oncologist, and a radiation oncologist. Patients received three cycles of neoadjuvant chemotherapy; 51 received cisplatin 100 mg/m2 day 1 plus gemcitabine 1250 mg/m2 days 1 and 8 every 21 days, and four received carboplatin AUC=5 day 1 plus gemcitabine 1000 mg/m2 days 1 and 8 every 21 days. A thoracotomy was performed within four to five weeks after the last chemotherapy cycle; the surgical procedure was based on the extent of tumor at the time of the initial presentation.
    • BRCA1 Gene Expression Analysis by RT-QPCR
  • We examined BRCA1 gene expression in formalin-fixed, paraffin-embedded surgical resected specimens from the 55 patients as previously described: Specht K, et al. (2001) Am. J. Pathol., 158, 419-429: “Quantitative gene expression analysis in microdissected archival formalin-fixed and paraffin-embedded tumor tissue”; Krafft A E, et al. (1997) Mol. Diagn., 3, 217-230: “Optimization of the isolation and amplification of RNA from formalin fixed, paraffin-embedded tissue: The Armed Forces Institute of Pathology experience and literatura review”. After standard tissue sample deparaffinization using xylene and alcohols, samples were lysed in a tris-chloride, EDTA, sodium dodecyl sulphate (SDS) and proteinase K containing buffer. RNA was then extracted with phenol-chloroform-isoamyl alcohol followed by precipitation with isopropanol in the presence of glycogen and sodium acetate. RNA was resuspended in RNA storage solution (Ambion Inc; Austin Tex., USA) and treated with DNAse I to avoid DNA contamination. cDNA was synthesized using M-MLV retrotranscriptase enzyme. Template cDNA was added to Taqman Universal Master Mix (AB; Applied Biosystems, Foster City, Calif., USA) in a 12.5-μl reaction with specific primers and probe for each gene. The primer and probe sets were designed using Primer Express 2.0 Software (AB). Quantification of gene expression was performed using the ABI Prism 7900HT Sequence Detection System (AB). Primers and probe for BRCA1 mRNA expression analysis were designed according to the Ref Seq NM—007294 (www.ncbi.nlm.nih.gov/LocusLink). Forward primer is located in exon 8 (position 4292 bp to 4317 bp), reverse primer in exon 9 (position 4336 bp to 4360 bp), and probe in the exon 8/9 junction (position 4313 bp to 4333 bp). The PCR product size generated with these primers was 69 bp. The primers and 5'labeled fluorescent reporter dye (6FAM) probe were as follows: β-actin: forward 5′ TGA GCG CGG CTA CAG CTT 3′, reverse 5′ TCC TTA ATG TCA CGC ACG ATT T 3′, probe 5′ ACC ACC ACG GCC GAG CGG 3′; BRCA1: forward 5′GGC TAT CCT CTC AGA GTG ACA TTT TA 3′, reverse 5′ GCT TTA TCA GGT TAT GTT GCA TGG T 3′, probe 5′CCA CTC AGC AGA GGG 3′.
  • Relative gene expression quantification was calculated according to the comparative Ct method using β-actin as an endogenous control and commercial RNA controls (Stratagene, La Jolla, Calif.) as calibrators. Final results, were determined as follows: 2−(ΔCt sample−ΔCt calibrator), where ΔCT values of the calibrator and sample are determined by subtracting the CT value of the target gene from the value of the β-actin gene. In all experiments, only triplicates with a standard deviation (SD) of the Ct value <0.20 were accepted. In addition, for each sample analyzed, a retrotranscriptase minus control was run in the same plate to assure lack of genomic DNA contamination (FIG. 1).
    • Statistical Methods
  • In order to provide an easily interpretable evaluation of the effect of BRCA1 mRNA expression, gene expression values were divided into quartiles. Interpatient variation coefficients were calculated to assess similarities between quartiles. Hazard ratios were calculated with the univariate Cox model, and comparison between Kaplan-Meier survival curves was performed with the log-rank test. All tests of statistical significance were two-sided, with a statistical power of 80%, and significance was set at 0.05 except in multiple comparisons, where it was set at 0.017 in accordance with the Bonferroni correction.
    • Results
  • Median survival was 37.8 months (95% CI, 27-48.5 months) for all patients, 51.9 months (95% CI, 31.6-72.4 months) for patients who underwent lobectomy, and 25.8 months (95% CI, 12.7-38.8 months) for those who underwent pneumonectomy. BRCA1 was detected in all tumors, although there was considerable variation in its level of expression, with values relative to the β-actin internal control ranging approximately 37-fold, from 0.28 to 10.43.
  • Amplification plots obtained for the genes BRCA1 and β-actin are shown in FIG. 1. Values ranged from 0.28 to 0.61 (interpatient coefficient of variation, 30.7%) for the 15 patients in the bottom quartile, from 0.65 to 1.20 (interpatient coefficient of variation, 17.4%) for the 14 patients in the second quartile, from 1.23 to 2.37 (interpatient coefficient of variation, 17.7%) for the 14 patients in the third quartile, and from 2.45 to 10.43 (interpatient coefficient of variation, 54.7%) for the 12 patients in the top quartile. Due to the similar values and interpatient coefficients of variation observed in the second and third quartiles, these two groups were merged for statistical analyses.
  • No differences in clinical characteristics were observed according to quartiles of BRCA1 mRNA expression levels (Table 1). However, for patients in the bottom quartile, radiographic response tended to be higher than for those in the middle or top quartiles (66.7%, 57.1%, 58.3%, respectively), complete resection was attained more often (93.3%, 78.6%, 83.3%, respectively), and a lobectomy was performed more often (73.3%, 32.1% [P=0.005], 58.3% [P=0.2], respectively).
  • TABLE 1
    Patient characteristics according to BRCA1 mRNA expression levels
    (bottom quartile vs two middle quartiles vs top quartile)
    Bottom Middle
    Quartile Quartiles
    of BRCA1 of BRCA1 Top Quartile of
    Levels Levels BRCA 1 Levels
    (0.28-0.61) (0.65-2.37) (2.45-10.43)
    N (%) N (%) N (%)
    Sex
    Female 3 (20)    3 (10.7) 0
    Male 12 (80)   25 (89.3) 12 (100)  
    Age
    Median, range 60 (49-74)  65 (51-76) 61 (45-71)
    Histology
    Squamous cell carcinoma 5 (33.3) 16 (57.1) 5 (41.7)
    Adenocarcinoma 7 (46.7) 11 (39.3) 2 (16.7)
    Large cell carcinoma 3 (20)   1 (3.6) 5 (41.7)
    Initial staging
    IIB: T3N0 2 (13.3) >3 (10.7) 1 (8.3) 
    IIIA: T3N1 0 1 (3.6) 3 (25)  
    T1N2 0 0 0
    T2N2 1 (6.7)   6 (21.4) 1 (8.3) 
    T3N2 3 (20)   7 (25)  2 (16.7)
    IIIB: T4N0 6 (40)    8 (28.6) 3 (25)  
    T4N1 1 (6.7)  2 (7.1) 1 (8.3) 
    T4N2 2 (13.3) 1 (3.6) 1 (8.3) 
    Chemotherapy Regimen
    Gemcitabine/Cisplatin 15 (100)   26 (92.9) 10 (83.3) 
    Gemcitabine/Carboplatin 0 2 (7.1) 2 (16.7)
    Radiographic Response
    Partial Response 10 (66.7)  16 (57.1) 7 (58.3)
    Stable Disease 5 (33.3) 10 (35.7) 4 (33.3)
    Progressive Disease 0 2 (7.1) 1 (8.3) 
    Surgical Results
    Complete Resection 14 (93.3)  22 (78.6) 10 (83.3) 
    Incomplete Resection 1 (6.7)   5 (17.9) 2 (16.7)
    Unresectable 0 1 (3.6) 0
    Surgical Procedures
    Lobectomy 11 (73.3)   9 (32.1) 7 (58.3)
    Pneumonectomy 4 (26.7) 14 (50)   5 (41.7)
    Bilobectomy 0  4 (14.3) 0
    Unresectable 0 1 (3.6) 0
  • Median survival was not reached for the 15 patients in the bottom quartile, while for the 28 in the two middle quartiles, it was 37.8 months (95% CI, 10.6-65), and for the 12 patients in the top quartile, it was 12.7 months (95% CI, 0.28-28.8) (P=0.01) (FIG. 2). Five patients who attained a complete pathologic response (T0N0) were all in the bottom quartile of BRCA1 levels (Table 2):
  • TABLE 2
    BRCA1 mRNA levels and clinical stage in patients who attained complete
    pathologic response after neoadjuvant chemotherapy followed by surgery.
    BRCA1 mRNA Pre-Treatment Post-Treatment Pathologic
    Patient Levels Clinical Stage Clinical Stage Stage
    1 0.31 T3N2 T2N0 T0N0
    2 0.28 T2N2 T1N0 T0N0
    3 0.30 T4N2 T2N1 T0N0
    4 0.33 T4N2 T2N0 T0N0
    5 0.34 T4N1 T4N1 T0N0
  • Conversely, in the majority of patients with high BRCA1 levels, no clinical or pathologic downstaging was observed following chemotherapy and surgery (Table 3):
  • TABLE 3
    Correlation of clinical and pathologic stage in patients in the
    top quartile of BRCA1 mRNA expression.
    mRNA BRCA1 Pre-Treatment Post-Treatment Pathologic
    Patient Levels Clinical Stage Clinical Stage Stage
    1 2.8 T3N2 T3N2 T2N2
    2 5.5 T2N2 —* T2N0
    3 10.43 T3N1 T2N0 T2N0
    4 2.45 T3N0 T3N0 T3N0
    5 4.12 T4N0 T1N0 T4N0
    6 6.93 T4N2 T3N0 T2N0
    7 2.81 T4N1 T4N1 T3N1
    8 3.09 T3N1 T2N0 T2N0
    9 5.61 T3N1 T2N0 T2N0
    10 3.36 T3N2 T3N2 T2N2
    11 2.8 T4N0 T3N0 T3N0
    12 2.62 T4N0 T4N0 T2N0
    *data not available
  • When patients were stratified by pathologic stage, those in the bottom quartile had a decreased risk of death (HR=0.206; 95% CI, 0.05-0.83; P=0.026) compared to those in the top quartile, and those in the two middle quartiles also had a decreased risk of death (HR=0.294; 95% CI, 0.10-0.83; P=0.020) compared to those in the top quartile. When patients were stratified by clinical stage, a similar pattern was observed. Those in the bottom quartile had a decreased risk of death (HR=0.220; 95% CI, 0.06-0.77; P=0.018) compared to those in the top quartile, and those in the two middle quartiles also had a decreased risk of death (HR=0.430; 95% CI, 0.17-1.1; P=0.078) compared to those in the top quartile. Thus, patients with low BRCA1 mRNA levels (bottom quartile) obtain the maximum benefit of neoadjuvant gemcitabine/cisplatin chemotherapy.

Claims (7)

1. A method for treating a patient with non-small-cell lung cancer having low expression levels of the BRCA1 gene comprising, administering to the patient cisplatin.
2. The method according to claim 1, wherein cisplatin is in a combination of gemcitabine/cisplatin.
3. A method for treating a patient with non-small-cell lung cancer having low expression levels of the BRCA1 gene comprising, administering to the patient docetaxel and/or paclitaxel.
4. The method according to claim 3, wherein the docetaxel is in a combination of gemcitabine/docetaxel and/or the paclitaxel is in a combination of gemcitabine/paclitaxel.
5. A method for classifying patients suffering from non-small-cell lung cancer comprising:
a) isolating mRNA from a cancerous tumor tissue sample of the patient;
b) determining the gene expression level of BRCA1 in the patient's sample; and
c) classifying the patient as either “low,” “normal,” or “high” by comparing the BRCA1 gene expression levels in the patient's sample with ranges of BRCA1 expression levels previously determined by measuring the BRCA1 expression levels of each within a collection of non-small-cell lung cancer tumor tissue biopsy samples previous to neoadjuvant chemotherapeutic treatment, and dividing the BRCA1 expression levels of all of the non-small-cell lung cancer tumor tissue biopsy samples into quartiles, wherein the patient is classified as “low” if the BRCA1 expression level in the patient's sample is within the range of BRCA1 expression levels of the bottom quartile, “high” if the BRCA1 expression level is within the range of BRCA1 expression levels of the top quartile, and “normal” is the BRCA1 expression level is within the range of BRCA1 expression levels of the middle two quartiles.
6. The method according to claim 5, wherein the patient classified as “high” has an increased risk of death compared with the patients classified as “normal” or “low”.
7. The method according to claim 5, wherein the patient is suffering non-small-cell lung cancer prior to surgery.
US12/496,257 2004-10-29 2009-07-01 Method of determining a chemotherapeutic regimen for non-small-cell lung cancer based on brca1 expression Abandoned US20100009013A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/496,257 US20100009013A1 (en) 2004-10-29 2009-07-01 Method of determining a chemotherapeutic regimen for non-small-cell lung cancer based on brca1 expression

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/977,951 US7563570B2 (en) 2004-10-29 2004-10-29 Method of determining a chemotherapeutic regimen for non small cell lung cancer based on BRCA1 expression
US12/496,257 US20100009013A1 (en) 2004-10-29 2009-07-01 Method of determining a chemotherapeutic regimen for non-small-cell lung cancer based on brca1 expression

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/977,951 Continuation US7563570B2 (en) 2004-10-29 2004-10-29 Method of determining a chemotherapeutic regimen for non small cell lung cancer based on BRCA1 expression

Publications (1)

Publication Number Publication Date
US20100009013A1 true US20100009013A1 (en) 2010-01-14

Family

ID=36262444

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/977,951 Expired - Fee Related US7563570B2 (en) 2004-10-29 2004-10-29 Method of determining a chemotherapeutic regimen for non small cell lung cancer based on BRCA1 expression
US12/496,257 Abandoned US20100009013A1 (en) 2004-10-29 2009-07-01 Method of determining a chemotherapeutic regimen for non-small-cell lung cancer based on brca1 expression

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/977,951 Expired - Fee Related US7563570B2 (en) 2004-10-29 2004-10-29 Method of determining a chemotherapeutic regimen for non small cell lung cancer based on BRCA1 expression

Country Status (1)

Country Link
US (2) US7563570B2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016185406A1 (en) 2015-05-19 2016-11-24 Nadathur Estates Pvt. Ltd. Method for identification of a deficient brca1 function

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7563570B2 (en) * 2004-10-29 2009-07-21 Pangaea Biotech Method of determining a chemotherapeutic regimen for non small cell lung cancer based on BRCA1 expression
AU2006243337B2 (en) * 2005-05-04 2011-09-29 Syncore Biotechnology Co., Ltd Method of administering a cationic liposomal preparation comprising paclitaxel
ES2609388T3 (en) 2006-03-22 2017-04-20 Syncore Biotechnology Co., Ltd Treatment of triple receptor-negative breast cancer
EP2677039B8 (en) * 2006-05-10 2022-10-05 DxTerity Diagnostics Incorporated Detection of nucleic acid targets using chemically reactive oligonucleotide probes
PL217731B1 (en) * 2006-06-01 2014-08-29 Tomasz Byrski Detection of lowered response for chemotherapy with the use of cytostatics from a group of toxoids
WO2009039479A1 (en) * 2007-09-21 2009-03-26 H. Lee Moffitt Cancer Center And Research Institute, Inc. Genotypic tumor progression classifier and predictor
WO2009144155A1 (en) * 2008-05-30 2009-12-03 Pangaea Biotech, S.A. Method for prediciting the clinical outcome of patients with non-small-cell lung cancer treated with an anti-metabolite plus an anti-microtubule agent
AU2009253298A1 (en) * 2008-05-30 2009-12-03 Pangaea Biotech, S.A. Methods and reagents for predicting clinical outcome and customizing chemotherapy in lung cancer patients
WO2011058164A1 (en) 2009-11-13 2011-05-19 Pangaea Biotech, S.A. Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
DK2609216T3 (en) 2010-08-24 2016-09-12 Dana Farber Cancer Inst Inc Methods to predict anti-cancer response
CA3080441A1 (en) 2012-02-23 2013-09-06 The Children's Hospital Corporation Methods for predicting anti-cancer response
EP2885425B1 (en) * 2012-08-20 2017-07-26 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Expression of protein-coding and noncoding genes as prognostic classifiers in early stage lung cancer
CN114875153B (en) * 2022-06-18 2023-09-15 瓯江实验室 Non-small cell lung cancer accurate chemotherapy prediction target CRTAC1 and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7563570B2 (en) * 2004-10-29 2009-07-21 Pangaea Biotech Method of determining a chemotherapeutic regimen for non small cell lung cancer based on BRCA1 expression

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5562925A (en) * 1970-04-20 1996-10-08 Research Corporation Tech. Inc. Anti-tumor method
US4526988A (en) * 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
CA1264738A (en) * 1984-12-04 1990-01-23 Eli Lilly And Company Treatment of tumors in mammals
GB0110430D0 (en) 2001-04-27 2001-06-20 Medical Res Council Protein variants and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7563570B2 (en) * 2004-10-29 2009-07-21 Pangaea Biotech Method of determining a chemotherapeutic regimen for non small cell lung cancer based on BRCA1 expression

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016185406A1 (en) 2015-05-19 2016-11-24 Nadathur Estates Pvt. Ltd. Method for identification of a deficient brca1 function

Also Published As

Publication number Publication date
US7563570B2 (en) 2009-07-21
US20060094021A1 (en) 2006-05-04

Similar Documents

Publication Publication Date Title
US20100009013A1 (en) Method of determining a chemotherapeutic regimen for non-small-cell lung cancer based on brca1 expression
Sarhangi et al. Breast cancer in the era of precision medicine
Lee et al. Comprehensive analysis of RET and ROS1 rearrangement in lung adenocarcinoma
Ross et al. Comprehensive genomic profiling of epithelial ovarian cancer by next generation sequencing-based diagnostic assay reveals new routes to targeted therapies
Meindl et al. Hereditary breast and ovarian cancer: new genes, new treatments, new concepts
Bast Jr Molecular approaches to personalizing management of ovarian cancer
Yang et al. Cyclin-dependent kinase 2 is an ideal target for ovary tumors with elevated cyclin E1 expression
Nicolson et al. Thymidylate synthase expression and outcome of patients receiving pemetrexed for advanced nonsquamous non–small-cell lung cancer in a prospective blinded assessment phase II clinical trial
Park et al. EGFR mutation is associated with short progression-free survival in patients with stage III non-squamous cell lung cancer treated with concurrent chemoradiotherapy
Quek et al. Gastrointestinal stromal tumor: a clinical overview
EP3946338A1 (en) Methods of treating squamous cell carcinomas with farnesyltransferase inhibitors
Mori et al. Clinical outcomes of women with ovarian metastases of colorectal cancer treated with oophorectomy with respect to their somatic mutation profiles
Lee et al. Predicting survival in patients with advanced non-squamous non-small cell lung cancer: validating the extent of metastasis
CN104145030A (en) Markers for the diagnosis of lung cancer aggressiveness and genetic instability
Nakamura et al. Olaparib monotherapy for BRIP1-mutated high-grade serous endometrial cancer
Guo et al. Next-generation sequencing reveals high uncommon EGFR mutations and tumour mutation burden in a subgroup of lung cancer patients
Liang et al. Impact of EGFR mutation status on tumor response and progression free survival after first-line chemotherapy in patients with advanced non-small-cell lung cancer: a meta-analysis
Wang et al. Prognostic value of autophagy, microsatellite instability, and KRAS mutations in colorectal cancer
Lin et al. Neoadjuvant afatinib with paclitaxel for triple-negative breast cancer and the molecular characteristics in responders and non-responders
KR20250094718A (en) Use of Cyclin E1 Status as a Predictive Biomarker for Treating Cancer with WEE1 Inhibitors
Lim Management of oligometastasis and oligoprogression in patients with epidermal growth factor receptor mutation-positive NSCLC in the era of third-generation tyrosine kinase inhibitors
Masuda et al. Efficacy of platinum combination chemotherapy after first-line gefitinib treatment in non-small cell lung cancer patients harboring sensitive EGFR mutations
WO2016148969A1 (en) Kub5/hera as a determinant of sensitivity to dna damage
Choi et al. MYC amplification-conferred primary resistance to capmatinib in a MET-amplified NSCLC patient: a case report
Zelli et al. Concurrent RAS and RAS/BRAF V600E variants in colorectal cancer: more frequent than expected? a case report

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO PAY ISSUE FEE